Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
Oncology
osteosarcoma
score
bone sarcoma
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
low middle income countries
prognostic
RC254-282
3. Good health
DOI:
10.3389/fonc.2023.1148480
Publication Date:
2023-04-28T05:58:37Z
AUTHORS (11)
ABSTRACT
The outcomes of osteosarcoma in low middle income countries (LMICs) are different due to patients presenting advanced stages, resource constraints and the use non-high-dose-methotrexate (HDMTX)-based regimens. This study derived validated a prognostic score for that integrates biologic social factors is tailored from an LMIC setting using non-HDMTX-based protocol.A retrospective including enrolled treatment at single tertiary care centre India between 2003-19 was conducted. Baseline characteristics were extracted medical records survival noted. cohort randomised into derivation validation cohort. Multivariable Cox regression used identify baseline independently A identified further with estimation its predictive ability.594 eligible inclusion study. Around one-third had metastatic disease 59% residing rural areas. presence metastases (HR 3.39; p<0.001; score=3), elevated serum alkaline phosphatase (SAP) >450 IU/L 1.57; p=0.001; score=1) tumour size > 10 cm 1.68; be independent predicting inferior event free (EFS) included development score. Patients categorized as risk (score 0), intermediate 1-3) high (4-5). Harrell's c-indices 0.682, 0.608 0.657 respectively EFS derivation, whole respectively. timed AUC ROC 0.67 18-month cohorts while 36-month 0.68, 0.66 0.68 respectively.The describes among treated uniformly protocol. Tumor size, SAP derive good value outcomes. Social did not emerge determinants survival.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (59)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....